Navigation Links
Transposagen Announces Exclusive License with Charles River Laboratories for p53 and Bcrp TGEM™ Knockout Rat Models
Date:10/13/2010

LEXINGTON, Ky., Oct. 13 /PRNewswire/ -- Transposagen Biopharmaceuticals, Inc. (Transposagen), the worldwide leader in genetically modified rats, has announced today that it has entered into an exclusive marketing and distribution agreement with Charles River Laboratories, a leading global provider of research models and services.

The license includes two of Transposagen's high-value TGEM™ Knockout Rat Models, one rat line contains a mutation in the p53 gene, the most studied tumor suppressor, and one rat line contains a mutation in the Bcrp gene, encoding an important drug transporter. The p53 gene is the gene most commonly mutated in many human cancers. The p53 TGEM™ Knockout Rat Model recapitulates human cancers and is the only fully phenotyped p53 knockout rat model, now available with complete tumor spectrum and survival data.  

"Our p53 and Bcrp TGEM™  Knockout Rat Models, developed with our academic collaborators at the Hubrecht Institute in the Netherlands, are the first of their kind in the world," said Dr. Eric Ostertag, the President and CEO of Transposagen. "For the p53 TGEM™ Knockout Rat Model in particular, we have years of phenotyping data showing that this research model faithfully produces a wide variety of tumors. Add this to the outstanding breeding standards and quality control offered by our partner, Charles River Laboratories, and customers can be certain that they are getting a quality research model."

These two unique TGEM™ Knockout Rat Models will enhance Charles River's ability to provide its global clients with unique solutions in the drug development process from target validation to toxicology and carcinogenicity testing. Dr. Iva Morse, Corporate Vice President, Global Research Model Services at Charles River, commented, "Charles River is extremely pleased to offer knockout rat models to our clients for the first time by partnering with Transposagen Biopharmaceuticals, a leader in the creation of genetically modified rat models.  Knockout rat models are a new and emerging tool in drug discovery and development, and Transposagen's p53 and Bcrp TGEM™ Knockout Rat Models are expected to quickly become widely accepted for research in oncology and other therapeutic areas."  

About Transposagen Biopharmaceuticals:

Transposagen Biopharmaceuticals, Inc., a Lexington, KY based company, is the worldwide leader in the creation of unique genetically modified rat models.  The company's signature products, TKO™ Knockout Rat Models and TGEM™ Rat Models, mimic human diseases and are used for drug discovery and development research. The company also creates custom transgenic rat models to customer specifications. For more information or to request a custom rat model, visit www.transposagenbio.com.Contact:Jack Crawford145 Graham Ave.ASTeCC Bldg., Suite A217Lexington, KY 40506859-428-8561
'/>"/>

SOURCE Transposagen Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MKS Instruments Announces Third Quarter 2010 Earnings Conference Call
2. OLIGOMERIX, Inc. Announces Board Changes: Vic Micati Appointed Chairman and Jack Pasini Appointed Company Director and Chief Commercial Officer
3. Highland Capital Management Announces 100% Ownership of American HomePatient, Completes Successful Public to Private Transition For Leading Provider of Home Respiratory Therapy
4. Boston Scientific Announces Global Launch of Journey™ Guidewire
5. Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process
6. CORRECTED - Akorn, Inc. Announces Date Change for Third Quarter 2010 Earnings Release and Conference Call
7. Prime Therapeutics Announces URAC Accreditation
8. Regeneron Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
9. Cellectis bioresearch Announces Establishment of Subsidiary in the US
10. BioSpecifics Technologies Corp. Announces Initiation of Global Phase 3 Trial of XIAFLEX® for Treatment of Peyronies Disease
11. Titan Pharmaceuticals Announces Journal of the American Medical Association Publication of Phase 3 Probuphine™ Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , April 29, 2016 ... H1 2016" market research report that provides an ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s announced ... the company,s valve repair and stent business, healthcare ... places Abbott more firmly into patient monitoring.  Kalorama ... fastest growing device areas, with double-digit growth expected ... report,  Advanced Remote Patient Monitoring . ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 29, 2016 , ... On Tuesday, April 26, 2016 members of the HomeTown ... of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. , ... 70% tax credit to individuals and corporations which donate directly to a “rural hospital” ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for ... Island Park on Sunday, with sunny skies, a light breeze and temperatures in the ... , The 5k Run and Walk and 1-mile walk were held to ...
(Date:4/29/2016)... ... 2016 , ... The Wharton School of the University ... of the 2016 Wharton Business Plan Competition —as well as the Wharton ... the Committee Award for Most ‘Wow Factor,’ making them the first team in ...
(Date:4/29/2016)... Tarzana, CA (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type ... is to blame for the majority of skin cancer deaths. More than 10,000 people are ... average age at diagnosis is 62, it is the one of the most commonly diagnosed ...
(Date:4/29/2016)... ... April 29, 2016 , ... For those who skip ... meal to miss. That was among the many new lifestyle diet tips offered by ... Sharon Kleyne Hour® Power of Water® radio show. Bonny and Lawrence noted that because ...
Breaking Medicine News(10 mins):